Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $60,800.00 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $6.08, for a total value of $60,800.00. Following the completion of the transaction, the director now owns 83,863 shares in the company, valued at $509,887.04. This represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Rosty Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.04, for a total value of $4,807.84.
• On Monday, November 4th, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $4.31, for a total value of $10,477.61.

Fennec Pharmaceuticals Stock Performance

Shares of Fennec Pharmaceuticals stock opened at $6.08 on Friday. The stock has a market capitalization of $167.02 million, a price-to-earnings ratio of -60.79 and a beta of 0.34. The company has a debt-to-equity ratio of 9.86, a current ratio of 7.80 and a quick ratio of 7.64. The business has a 50-day moving average of $5.54 and a 200 day moving average of $5.52. Fennec Pharmaceuticals Inc has a 12 month low of $3.96 and a 12 month high of $11.49.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp lifted its holdings in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after buying an additional 7,053 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Fennec Pharmaceuticals by 42.8% in the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock valued at $420,000 after acquiring an additional 20,602 shares in the last quarter. WINTON GROUP Ltd purchased a new position in Fennec Pharmaceuticals in the second quarter valued at $409,000. Advantage Alpha Capital Partners LP purchased a new position in Fennec Pharmaceuticals in the third quarter valued at $264,000. Finally, Barclays PLC grew its stake in Fennec Pharmaceuticals by 274.3% during the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock worth $157,000 after purchasing an additional 22,951 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on FENC. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday, December 17th. Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Wedbush reiterated an “outperform” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Friday, December 20th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.